secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001650664-25-000123
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Q2 net loss $53.2M; selects in vivo lead candidate in Sept; BMS CAR T milestone triggered
--------------------------------------------------------------------------------

- Q2 net loss $53.2M ($0.63/share) vs $67.6M loss a year ago; revenue $3.6M from BMS milestone.
- Cash $178.5M at June 30 (down from $269.9M at Dec 2024); runway into Q2 2027.
- R&D expense fell $38M to $16.2M on reni-cel discontinuation; restructuring charges $26.1M.
- First IND/CTA accepted for CD19 HD Allo CAR T with BMS, triggering milestone payment to Editas.
- On track to name lead in vivo candidate Sept 2025, file IND mid-2026, achieve POC by end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000123/0001650664-25-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000123/edit-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001650664-25-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer